Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.46 |
| ▸ | FABP7 | O15540 | 2/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.43 |
| ▸ | ITGAV | P06756 | 1/20 | 0.43 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 3/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | PREP | P48147 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119867 | 1.00 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL4575275 | 1.00 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL29402209 | 1.00 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL29383097 | 1.00 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL30510359 | 1.00 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL29447672 | 1.00 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL17359219 | 0.99 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL30792899 | 0.99 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL27028706 | 0.99 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 | |
| SCHEMBL119560 | 0.96 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2RAB9AFABP5FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230135758-A1 | ELONGATION FACTOR 1-ALPHA INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-05-04 | — | — | US | disclosed |
| US-11229711-B2 | Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use | Magenta Therapeutics, Inc. (US) | 2022-01-25 | — | — | US | disclosed |
| EP-2813512-B1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-03-31 | — | — | EP | disclosed |
| CN-111356456-A | 2-arylsulfonamido-iV-arylacetamide derived Stat3 inhibitor | 夏威夷大学 | 2020-06-30 | — | — | CN | disclosed |
| WO-2018136935-A1 | 2-ARYLSULFONAMIDO-N-ARYLACETAMIDE DERIVATIZED STAT3 INHIBITORS | UNIVERSITY OF HAWAII (US) | 2018-07-26 | — | — | WO | disclosed |
| US-20080176841-A1 | EPOXIDE INHIBITORS OF CYSTEINE PROTEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
| US-20070224607-A1 | Methods for identifying compounds of interest using encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070224607-A1 | Methods for identifying compounds of interest using encoded libraries | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2007-09-27 | — | — | US | disclosed |
| WO-2007053358-A2 | METHODS FOR IDENTIFYING COMPOUNDS OF INTEREST USING ENCODED LIBRARIES | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070042401-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070042401-A1 | Methods for synthesis of encoded libraries | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | ALDH1A1 4838/4885SMN1; SMN2 4201/4885RAB9A 65/4885 |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | ALDH1A1 1732/4885SMN1; SMN2 3140/4885RAB9A 649/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | ALDH1A1 4838/4885SMN1; SMN2 4201/4885RAB9A 65/4885 |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | GALE, ENGASE, UGGT1 | ALDH1A1 1380/4885SMN1; SMN2 4258/4885RAB9A 2593/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | ALDH1A1 2546/4885SMN1; SMN2 1943/4885RAB9A 2724/4885 |
| US-11229711-B2 | Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use | CLSPN, SDCBP, DCLRE1A | ALDH1A1 2503/4885SMN1; SMN2 2731/4885RAB9A 2019/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | ALDH1A1 4838/4885SMN1; SMN2 4201/4885RAB9A 65/4885 |
| US-20230135758-A1 | ELONGATION FACTOR 1-ALPHA INHIBITORS AND USES THEREOF | EEF1A1, EEF1B2, EEF1G | ALDH1A1 3486/4885SMN1; SMN2 1658/4885RAB9A 2006/4885 |
| US-20080176841-A1 | EPOXIDE INHIBITORS OF CYSTEINE PROTEASES | SERPINB1, EPHX1, EPX | ALDH1A1 932/4885SMN1; SMN2 3949/4885RAB9A 3453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.